Search results for: Pricing and Reimbursement

Around The World in HTAs: The Slovak Republic – Valuing the Future

13 September 2023

…working groups, NIHO, and the Section of Pharmacy and Drug Policy. Expert working groups provide clinical assessments, NIHO provides technology assessments, and The Section of Pharmacy and Drug Policy issues…

Around the World in HTAs: United States – Making HTA Great Again

11 June 2024

…The system is made up of a complex mix of private and public insurance and is perceived by many to prioritise high-quality services and advanced technologies at the expense of…

The case for adopting a broader perspective on value in Health Technology Assessment

3 March 2026

…costs and patient outcomes. While this simplifies decision-making and reduces uncertainty, it systematically excludes indirect costs and spillover effects on carers, families, and society.  Adopting a broader perspective on value,…

Understanding the Full Value of Long-Acting Therapies: less is more?

7 May 2025

…and involve patients and their healthcare professionals to ensure that the development and implementation of LA therapies align with patient needs, health system improvements, and societal or economic goals. The…

New evaluation model finds widespread adoption of cell and gene therapies may unlock billions for the UK economy

20 October 2025

…individuals and their carers, resulting from extra years in work and reduced levels of care. It could also save the health and care service £19.9bn and could add £21.5bn to…

Economics of Innovation

…and advancing demand-side pricing and reimbursement policies and levers that balance affordability, access and incentives for innovation. Improving our understanding of the broad health and wider social value of innovation,…

Can and Should Value Based Pricing Be Applied to Molecular Diagnostics?

1 April 2012

…pricing and reimbursement systems for diagnostics, however, are not efficient and provide poor incentives… Diagnostics not only facilitate health gain and cost savings, but also provide information to inform patients’…

Can and Should Value Based Pricing Be Applied to Molecular Diagnostics?

1 May 2012

…affect their health in future.  Current pricing and reimbursement systems for diagnostics, however, are not efficient and provide poor incentives for new diagnostic approaches.  Prices often are driven by administrative…

OHE’s AMR consultation response

21 November 2023

…across 17 criteria that cover aspects of clinical effectiveness, global and national needs, pharmacological benefits, and health system benefits. Each criterion is associated with scores and a weight (Figure 1)…